Loading...

FGEN FIBROGEN INC Company Mergers 8-K Filing

FBRG

FGN

FIBROGEN INC

(FGEN)

2025 8-K

Show Summary

Summary

Asset Sale Completed

Acquisition Announcement

Financing Agreement Update

Debt-Equity Swaps

Divestment of Assets

Reverse Stock Split

Financial Statements

Bylaw Amendment

Drug Publication

Agreement Amendments

Financial Update

Equity Offering

Management Change

Q3 Financial Results

Lease Termination

Director Resignations

Executive Departures

Restructuring Plan

Financial Results and Busin...

Investor Presentation

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

Delisting Notice

Appointment of CEO and Dire...

Resignation of Chief Medica...

Financial Results Announcement

Appointments, resignations

Management changes

Annual Meeting of Stockholders

Positive Results from Phase...

Financial Results Announcement

Financing Agreement

External Links:

FibroGen Inc. announced on August 18, 2025, that it received Chinese regulatory approval to sell its subsidiary, FibroGen International (Hong Kong) Ltd., to AstraZeneca, with the deal expected to close in Q3 2025. This transaction allows FibroGen to retain rights for roxadustat in several regions outside of China.

AI Assistant

FIBROGEN INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.